Medline posts 10.7% Q1 sales growth but profits squeezed by tariffs
Medline Inc. has reported first-quarter 2026 net sales of $7.4 billion, a 10.7% increase year-on-year, as the Illinois-based medical-surgical products giant continued to onboard new customer signings from 2025. The top-line strength was, however, accompanied by a significant compression of margins, with net income falling 25.8% to $239 million and Adjusted EBITDA declining 10.6% to $776 million.
Chief executive Jim Boyle attributed the revenue momentum to successful implementation of large customer contracts and organic growth across the existing base. "We started 2026 with strong momentum — growing with our existing customers, executing implementations at scale and winning new customers," he said. The company responded to the underlying commercial confidence by lifting its full-year 2026 Organic Sales growth guidance to a range of 8.5% to 9.5%, up from the prior 8% to 9%, while maintaining its Adjusted EBITDA outlook of $3.5 to $3.6 billion.
Margin pressure: tariffs and IPO costs in focus
The profitability shortfall reflects a combination of structural and one-off cost pressures. Cost of goods sold rose 14.3% — faster than revenue — as tariff headwinds fed through to sourcing costs. Selling, general and administrative expenses climbed 14.8%, partly to resource the ramp of new customer implementations, and the quarter also absorbed $27 million in IPO-related expenses including legal, accounting, and advisory fees alongside one-time employee bonuses tied to the company's recent Nasdaq listing. Strip those items out and the adjusted Diluted EPS stands at $0.33, compared with a reported diluted figure of $0.16.
Free cash flow came in at $316 million, down sharply from $584 million in the same period of 2025, largely because operating cash flows were depressed by rising trade receivables and higher inventory balances associated with the enlarged customer book. Net leverage at the end of the quarter stood at 3.1 times Adjusted EBITDA on a trailing twelve-month basis, against a total net debt position of approximately $10.5 billion.
Competitive landscape and tariff read-across
Medline's tariff exposure is a concern shared across the broader med-surg distribution and manufacturing sector. The company sources a significant proportion of its product portfolio from Asian manufacturing bases, and the current US trade policy environment — with elevated tariffs on goods from several major sourcing countries — is compressing gross margins industry-wide. Competitors such as Cardinal Health and Owens & Minor face analogous pressures, though Medline's scale and its dual positioning as both a branded manufacturer (the Medline Brand segment, which reported $3.5 billion in Q1 sales) and a supply chain solutions provider ($3.9 billion) gives it a degree of procurement leverage that smaller pure-play distributors lack.
The Medline Brand segment bore the heavier earnings impact, with Adjusted EBITDA falling 7.8% to $765 million and margin contracting from 25.4% to 22.1%. The Supply Chain Solutions segment was comparatively resilient, with Adjusted EBITDA up 2.7% to $187 million, though its margin also tightened slightly.
Looking ahead, investor attention will focus on whether the tariff drag stabilises or intensifies through the second half of the year, and on whether the newly onboarded customer base begins to generate the operating leverage needed to rebuild margins. The company's guidance implies confidence in volume, but Adjusted EBITDA guidance was held flat, signalling management's caution about the cost environment for the remainder of 2026.